Sciclone Pharmaceuticals (SCLN) Inactive 10-K2016 FY Annual report

Filed: 9 Mar 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: anticancer, AskCI, behavior, bought, bridging, categorized, chemoradiation, Chiesi, circumstance, compel, compound, consumption, cycle, dispersed, dusquetide, Endoxan, explained, exploited, Farmaceutici, GAAP, head, impracticable, inadvertently, intent, intention, investee, Jiangsu, library, Media, multiple, neck, negligent, occasional, offshore, opposed, organizational, OTCQB, owe, perception, Pharmacopeia, Phosplatin, PRDL, recover, remuneration, residual, retention, Roth, SL, Soligenix, split, substance, territorial, territory, timeframe, unclear, undertook, underway, unregistered, unrepatriated, unstable, USA, variable

Removed: abandon, accretion, acquirer, acquiring, aim, alleged, allegedly, Alternatively, anticorruption, Arbitral, arise, arterial, augmenting, authorize, automated, binding, BioFutura, bribery, bring, broader, canceled, central, cessation, civil, clear, consultation, contemplating, continual, corrective, Correvio, corruption, dealing, delaying, deteriorating, deterring, developing, diminished, disadvantage, disruption, educational, enforcing, entertainment, entitle, erode, extortion, faced, film, forbidden, formula, found, geopolitical, heightened, hospital, identification, IDL, image, impair, impede, impermissible, implementing, improper, improperly, improving, inception, induced, Injury, instability, integration, intensely, interfere, introduced, investigating, lesser, letter, liberalization, lieu, linked, Liposome, LLC, lowering, marketplace, Mellon, misappropriation, multinational, nausea, ninety, North, notification, null, observe, ondansetron, onset, optimize, override, pace, PAD, passed, peripheral, permissible, plaque, preferential, prescription, prevented, pro, procurement, ProFlow, prompt, Proposal, put, RapidFilm, rata, Ratification, reclassified, recommendation, redeemed, refund, relied, remedial, renegotiating, replaced, reputational, researcher, residence, respiratory, respond, retaliate, Retaliation, revoke, role, rule, Sanofi, securing, separation, Srl, stockpile, superior, suspend, target, targeted, theft, thereof, threat, threatening, TLC, training, Tramadol, travel, trend, Tribunal, turmoil, unified, unprofitable, upsurge, violate, violated, void, weaker, whistleblower, workforce, worsen

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SCLN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S‑3 (Nos. 333-52471, 333-62309, 333-77543, 333-81481, 333-84487, 333-85673, 333-30938, 333-72800, 333-107538 and 333-176209) and Form S-8 (Nos. 333-12169, 333-62059, 333-45820, 333-98081, 033-66832, 333-109256, 333-120008, 333-128482, 333-145281, 333-168668, 333-183171, 333-205554 and 333-213012) of SciClone Pharmaceuticals, Inc. of our report dated March 9, 2017 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.

/s/ PricewaterhouseCoopers Zhong Tian LLP

Shanghai, the People’s Republic of China
March 9, 2017